|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: MAXALT
Summary for Tradename: MAXALT
|
| |||||||||||
Clinical Trials for: MAXALTStudy of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops Status: Recruiting Condition: Chronic Post-traumatic Headache Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029) Status: Completed Condition: Migraine Disorders Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1) Status: Completed Condition: Migraine Disorders Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Status: Completed Condition: Migraine With Aura; Migraine Without Aura Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)(COMPLETED) Status: Completed Condition: Migraine Headache A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7) Status: Completed Condition: Migraine, Acute MK0462 in Treatment of Migraine With Recurrence (MK0462-022)(COMPLETED) Status: Completed Condition: Migraine Headache Two Rizatriptan Prescribing Portions for Treatment of Migraine Status: Completed Condition: Migraine A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3) Status: Completed Condition: Acute Migraine With or Without Aura in Adolescents MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)(COMPLETED) Status: Completed Condition: Migraine Headache Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck | MAXALT | rizatriptan benzoate | TABLET; ORAL | 020864 | Jun 29, 1998 | RX | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merck | MAXALT | rizatriptan benzoate | TABLET; ORAL | 020864 | Jun 29, 1998 | RX | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merck | MAXALT | rizatriptan benzoate | TABLET; ORAL | 020864 | Jun 29, 1998 | RX | No | 5,298,520*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merck | MAXALT | rizatriptan benzoate | TABLET; ORAL | 020864 | Jun 29, 1998 | RX | No | 5,602,162*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: MAXALT
| Drugname | Dosage | Strength | RLD | Submissiondate |
| rizatriptan benzoate | Orally Disintegrating Tablets | 5 mg and 10 mg | Maxalt-MLT | 2/17/2006 |
| rizatriptan benzoate | Tablets | 5 mg and 10 mg | Maxalt | 9/2/2004 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc